Related Experiment Video
Updated: Mar 9, 2026

Author Spotlight: Eco-friendly Photoluminescent Textile Authentication with Curcumin
Published on: December 22, 2023
Recent progress on curcumin-based therapeutics: a patent review (2012-2016). Part I: Curcumin
Rita Maria Concetta Di Martino1, Barbara Luppi1, Alessandra Bisi1
1a Department of Pharmacy and Biotechnology , Alma Mater Studiorum-Bologna University , Bologna , Italy.
Introduction:
curcumin is the main bioactive component contained in Curcuma Longa, largely employed in traditional medicine. Recently, beneficial properties, useful for prevention and treatment of several disorders, have been discovered for this compound. Peculiar structural feature is an α,β-unsaturated carbonyl system essential for establishing contacts with critical cysteine residues of several targets. This distinctive mechanism of action imparts to the molecule the ability to affect a large number of targets, accounting for its pleiotropic behaviour and definition of "privileged structure". Areas covered: The objective of the review is an examination of the recent developments in the field of the anti-cancer applications of curcumin, together with formulation issues, considering the patent literature in the years 2012-2016. Expert opinion: The wide therapeutic efficacy of curcumin is related to synergistic interactions with several biological targets, along with the modulation of several signaling pathways. This peculiar behaviour could be useful in the treatment of multifactorial diseases such as cancer. Combination of curcumin with a first line antineoplastic drug proved to be a valuable strategy to obtain an amplified response with minimized side effects. Innovative curcumin formulations based on the nanotechnology approach allowed improving both bioavailability and therapeutic efficacy.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Therapeutic Index
Preclinical Development: Overview

